Skin Ulcers without CC/MCC DRG Reimbursement Guide

DRG 594 encompasses inpatient stays for skin ulcers without Complication or Comorbidity or Major Complication or Comorbidity, focusing on wound management and related interventions. Accurate coding and documentation of ulcer etiology and the absence of Complication or Comorbidity or Major Complication or Comorbidity are important because they determine the Medicare payment and hospital case-mix classification.

DRG 594 Overview

DRG 594 covers inpatient admissions for patients treated primarily for skin ulcers when no Complication or Comorbidity or Major Complication or Comorbidity is present. It includes clinical management such as wound care, debridement, infection control, and evaluation for underlying causes like pressure, venous insufficiency, or arterial disease. This Diagnosis-Related Group matters because it groups expected resource use and establishes the Medicare payment for uncomplicated ulcer cases, affecting hospital reimbursement and case-mix reporting.

DRG 594 Overview

Studies of wound care interventions in hospitalized patients with stage III-IV pressure ulcers or chronic lower-extremity ulcers, comparing advanced dressings, biologic agents, or negative-pressure wound therapy versus standard moist wound care. These trials enroll inpatients who require debridement or intensive nursing care and measure time to wound closure, infection rates, need for surgical procedures, and resource utilization during the hospital stay. Results are highly relevant to providers for selecting effective acute wound management strategies and to payers for understanding inpatient length of stay, procedure use, and cost implications associated with different acute care pathways.
Comparative effectiveness trials assessing debridement techniques and perioperative infection prevention in patients with skin ulcers that are complicated by comorbidities such as diabetes or peripheral vascular disease. These studies focus on subgroups at higher risk for poor healing and examine outcomes like re-hospitalization, limb salvage, and short-term complication rates, often tracking care across the inpatient episode into the immediate post-discharge period. Findings inform clinical decision-making about which surgical or bedside debridement approaches and prophylactic care bundles reduce complications and downstream costs for medically complex patients within this DRG.
Post-discharge outcomes and care-coordination studies evaluating transitional care models, home health nursing intensity, and readmission reduction interventions for patients discharged after inpatient treatment of skin ulcers without major complications. These observational or pragmatic randomized studies follow patients through 30–90 days post-discharge to measure wound recurrence, emergency visits, readmissions, and outpatient resource use. For providers and payers, this research identifies which discharge planning and outpatient support strategies improve recovery, lower short-term readmission risk, and optimize total episode-of-care spending for this patient group.

Studies of wound care interventions in hospitalized patients with stage III-IV pressure ulcers or chronic lower-extremity ulcers, comparing advanced dressings, biologic agents, or negative-pressure wound therapy versus standard moist wound care. These trials enroll inpatients who require debridement or intensive nursing care and measure time to wound closure, infection rates, need for surgical procedures, and resource utilization during the hospital stay. Results are highly relevant to providers for selecting effective acute wound management strategies and to payers for understanding inpatient length of stay, procedure use, and cost implications associated with different acute care pathways.
Comparative effectiveness trials assessing debridement techniques and perioperative infection prevention in patients with skin ulcers that are complicated by comorbidities such as diabetes or peripheral vascular disease. These studies focus on subgroups at higher risk for poor healing and examine outcomes like re-hospitalization, limb salvage, and short-term complication rates, often tracking care across the inpatient episode into the immediate post-discharge period. Findings inform clinical decision-making about which surgical or bedside debridement approaches and prophylactic care bundles reduce complications and downstream costs for medically complex patients within this DRG.
Post-discharge outcomes and care-coordination studies evaluating transitional care models, home health nursing intensity, and readmission reduction interventions for patients discharged after inpatient treatment of skin ulcers without major complications. These observational or pragmatic randomized studies follow patients through 30–90 days post-discharge to measure wound recurrence, emergency visits, readmissions, and outpatient resource use. For providers and payers, this research identifies which discharge planning and outpatient support strategies improve recovery, lower short-term readmission risk, and optimize total episode-of-care spending for this patient group.

OpenPayer

Skin Ulcers without CC/MCC: Inpatient Reimbursement Overview

Sign up for drg 594 policy alerts

DRG 594 Overview

OpenPayer

Skin Ulcers without CC/MCC: Inpatient Reimbursement Overview

Sign up for drg 594 policy alerts

DRG 594 Overview

Clinical Trials

Related Codes

References

Clinical Trials

Related Codes

References